September 30, 2016 4:24 AM ET

Health Care Technology

Company Overview of Definiens AG

Company Overview

Definiens AG provides biomedical image analysis and data mining software solutions for life sciences, tissue diagnostics, and clinical digital pathology markets. It offers Definiens Tissue Studio, a solution for biomarker and morphological profiling in research and drug discovery on tissue samples, as well as detects regions of interest and distinguishes cell types and cell subtypes within target regions across various tissue slides; and Definiens Developer XD, a solution for scientists and image analysis experts to create and validate automated solutions for a range of biomedical image analysis problems. The company also provides Definiens Image Miner, a solution that integrates data mining...

Bernhard-Wicki-Straße 5

Munich,  80339


Founded in 1994


49 89 2311800


49 89 23118090

Key Executives for Definiens AG

Chief Executive Officer
Founder, Chief Technology Officer and Director
Chief Financial Officer
Chief Operating Officer
Compensation as of Fiscal Year 2016.

Definiens AG Key Developments

Definiens Expands Boston-Based Office in Response to Growth in U.S. Market

Definiens announced that it is expanding its presence in the U.S. to meet growing customer needs. The company opened its Boston office last year, and since then has experienced significant growth in providing tissue-based services to pharmaceutical companies, academic medical centers, comprehensive cancer centers and biotech companies in North America, prompting further expansion in the market. The office, based just outside Boston in Cambridge, MA, will become the company’s new U.S. headquarters. The company will continue to focus on enhancing its offerings for customers, and as part of that will be recruiting additional technical engineering employees as well as commercial leaders for the Boston office.

Definiens Releases Tissue Studio 4.3 and Developer XD 2.6 to Meet Quantification Demands in Translational Research

Definiens announced the release of the Tissue Studio 4.3 and Developer XD 2.6 software packages. The updated product suites provide scientists, clinicians and researchers working in translational research and immuno-oncology with powerful, fast image analysis solutions that can easily be tailored to their specific needs, yielding the most accurate, quantitative answers to their questions and accelerating the discovery of meaningful results. Definiens Tissue Studio is an image analysis solution for biomarker and morphological profiling in research and drug discovery on tissue samples. The fully flexible, scalable solution provides the best quality in quantification and highly reliable data generation. Developer XD is a flexible development environment designed to enable the creation of comprehensive automated image analysis solutions. It solves even the most challenging segmentation and classification tasks to gain a deeper understanding of the underlying biology. The updated Tissue Studio includes enhanced functionality to meet the current and future quantification demands across the spectrum of drug discovery and development, from basic research to translational studies. The software provides quantitative assessment of immune cell subpopulations in tumor tissue sections, enabling improved understanding of disease and drug mechanisms in immune-oncology. Specific enhancements are listed below. Tissue Studio® 4.3: Separate analysis of multiple tissue sections on a single slide: Users can save slides and increase reliability of their study by adding more than one section from the tissue block onto a single glass slide. Analysis of those different tissue sections is separated so users can receive distinct data for each section as if they were on different slides. Quantification of immune response: Users can add a configurable margin around their ROIs to quickly and robustly quantify immune response in tumor core and margin regions. Removal of tiling artifacts: The software prevents border artifacts for accurate object detection and measurements. Precise export of ISH measurements: Users can receive high quality statistics from advanced (RNA/DNA) ISH assays by identifying and exporting the location of single spots within each cell. Developer XD 2.6: Novel algorithms: New algorithms such as MSER, Color Deconvolution, Image Object Convex Hull and others are available to allow the user to solve any image analysis problem. Improved integration with PerkinElmer Vectra® and Mantra™ multispectral imaging systems: Users can obtain novel insights by quantifying multispectral fields of views in the context of the full slide.

Definiens AG Presents at 2016 BIO International Convention, Jun-09-2016

Definiens AG Presents at 2016 BIO International Convention, Jun-09-2016 . Venue: Moscone Center, San Francisco, California, United States. Speakers: Merrilyn Datta, chief commercial officer.

Similar Private Companies By Industry

Company Name Region
Aiomed GmbH Europe
AnagnosTec Gmbh Europe
ArtCline GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Definiens AG, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at